logo
  Join        Login             Stock Quote

Complete Genomics (GNOM) Loss Narrows, Revenue Soars In 3Q

 November 09, 2012 07:03 AM


(By Balachander) Complete Genomics Inc. (NASDAQ: GNOM), a provider of human genome sequencing technology, reported a narrower loss for the third quarter as revenue jumped.

Net loss narrowed to $17.99 million or 52 cents per share from $21.60 million or 65 cents per share in the year-ago quarter.

Revenue soared 74 percent to $7.28 million and the company recognized revenue for roughly 1,900 genomes.

Wall Street analysts, on average, expected a loss of 52 cents per share on revenue of $8.05 million.

Costs and operating expenses fell slightly to $24.6 million from $25.0 million in the comparable period of the prior year.

[Related -Illumina (ILMN) Says Court Agrees To Review Patent Decision]

Complete Genomics, which had announced a merger agreement with Chinese pharmaceutical company BGI-Shenzhen, said it ended the third quarter with $34.7 million in cash, cash equivalents, and short-term investments. This included $6.0 million received from a subsidiary of BGI-Shenzhen.

Under the terms of the agreement entered in September, the Mountain View, California-based developer of DNA sequencing platform will be acquired by a U.S. unit of BGI for $3.15 per share in cash.

As of September 30, 2012, the company's backlog was around 3,800 revenue generating genomes, representing an aggregate revenue potential of roughly $18 million.

For the second quarter ended June 30, the company posted a wider loss as 29 percent rise in costs and expenses offset 48 percent rise in revenue. Its net loss widened to $18.8 million from $15.9 million on revenue of $8.6 million.

[Related -Stocks Retreat On Factory Data, Europe; Waste Connections (WCN) Jumps]

GNOM ended Thursday's regular trading session at $3.00. The stock has been trading in the 52-week range between $1.57 and $5.42.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageFour Stocks in the Dow Making Fresh 52 Week Lows

“What gets weak tends to get weaker; what gets strong tends to get read on...

article imageGreece And The Cemetery For Your Wealth

The Greek default is merely the opening act of the worst sovereign-debt crisis in history. By the time it read on...

article imageAll Signs Point To Higher Gold Prices

In the face of historic monetary stimulus from nearly every major central bank in the world over the past read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.